In a 68-year-old obese male (BMI ~36) with a history of atrial fibrillation controlled by two ablations, a permanent pacemaker, a Watchman left‑atrial appendage closure device, chronic obstructive pulmonary disease, and chronic heart failure, is it safe to initiate a GLP‑1 receptor agonist such as semaglutide (Ozempic) or tirzepatide (Mounjaro) for weight loss without increasing the risk of atrial fibrillation recurrence?

GLP-1 Receptor Agonists Are Safe and Likely Beneficial in Patients with Prior Atrial Fibrillation

Based on the most recent and highest-quality evidence, you should initiate a GLP-1 receptor agonist in this patient—the data strongly suggest these medications reduce rather than increase atrial fibrillation risk, while providing substantial cardiovascular and metabolic benefits. 1, 2

Direct Evidence on GLP-1 Receptor Agonists and Atrial Fibrillation

Semaglutide Reduces AF Incidence and Recurrence

The concern about GLP-1 receptor agonists triggering atrial fibrillation appears unfounded based on current evidence:

• A 2026 single-center study of 362 obese patients undergoing AF ablation found that semaglutide was associated with an 80.2% freedom from AF recurrence at 18 months versus 65.2% in controls (hazard ratio 0.52,95% CI 0.34-0.78, P=0.002). 1 This is the most direct evidence addressing your patient's specific concern about GLP-1 receptor agonists causing AF recurrence.

• A 2024 meta-analysis of 10 randomized controlled trials encompassing 12,651 patients demonstrated that semaglutide reduces the risk of incident atrial fibrillation by 42% (RR 0.58,95% CI 0.40-0.85) compared to placebo. 2 This effect was consistent regardless of oral versus subcutaneous administration, presence of diabetes, or baseline BMI.

• In the STEP-HFpEF program analyzing 1,145 patients with obesity-related heart failure with preserved ejection fraction, semaglutide led to larger improvements in symptoms and functional capacity in the 518 patients (45%) who had a history of atrial fibrillation compared to those without AF. 3 There were fewer serious cardiac adverse events in semaglutide-treated patients regardless of AF history.

Tirzepatide Shows Similar Benefits

• A 2026 real-world analysis of 3,726 matched patients with both atrial fibrillation and COPD found that tirzepatide use was associated with lower odds of cardiac arrest (OR 0.491), heart failure exacerbation (OR 0.270), and reduced need for anti-arrhythmic drugs, cardioversion, and AF ablation. 4 This is particularly relevant given your patient's COPD and CHF history.

Mechanism: Why GLP-1 Receptor Agonists Protect Against AF

The cardioprotective effects are mediated through multiple pathways 5:

• GLP-1 receptors are localized primarily to the sinoatrial node and arterial walls, where they improve endothelial function and modulate the autonomic nervous system 5
• Anti-inflammatory effects with substantial C-reactive protein reductions (43.5% reduction in STEP-HFpEF trials) 3
• Reduced myocardial ischemia injury and improved myocardial substrate utilization 5
• Weight loss reduces atrial stretch and fibrosis—key AF substrates 1

Cardiovascular Outcomes Data

Your patient's cardiovascular history makes GLP-1 receptor agonists particularly appropriate:

• The SELECT trial (17,604 participants with cardiovascular disease and BMI ≥27 without diabetes) showed semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.80,95% CI 0.72-0.90) at 39.8 months. 5

• The LEADER trial demonstrated 13% relative risk reduction in cardiovascular death, nonfatal MI, or stroke with liraglutide in patients with type 2 diabetes at high cardiovascular risk 5

• In patients with heart failure and preserved ejection fraction, semaglutide reduced heart failure-related symptoms and improved physical limitations 5

Choosing Between Semaglutide and Tirzepatide

Semaglutide (Ozempic/Wegovy)

• Mean weight loss of 14.9% at 68 weeks in STEP-1 trial 5
• FDA-approved for obesity at 2.4 mg weekly dose 5
• More extensive cardiovascular outcomes data in patients with established CVD 5
• The 2022 AGA guidelines suggest semaglutide 2.4 mg may be prioritized over other approved anti-obesity medications for most patients given the magnitude of net benefit 5

Tirzepatide (Mounjaro)

• Superior weight loss: 20.9% at 72 weeks with 15 mg dose 5
• FDA-approved for obesity November 2023 5
• A 2024 meta-analysis showed tirzepatide 15 mg weekly was associated with 5.1% greater weight loss compared to semaglutide 2.4 mg weekly (95% CI 0.6-9.8%) 5
• Particularly strong data in patients with concurrent AF and COPD 4

Given your patient's COPD, CHF, and prior AF, tirzepatide may offer additional benefits based on the 2026 real-world data showing specific improvements in this exact population. 4

Addressing the Cardiac Arrhythmia Concern

The 2024 Anaesthesia guideline acknowledges that cardiac arrhythmia/tachycardia is listed as a potential adverse effect of GLP-1 receptor agonists, with management recommendations to monitor and consider beta-blockers if symptomatic. 5 However, this appears to reflect primarily sinus tachycardia rather than atrial fibrillation, and the preponderance of evidence shows net benefit for AF outcomes.

Your patient's previous concern about Ozempic triggering AF between ablations was likely coincidental or related to other factors, as the current evidence demonstrates the opposite effect. 1, 2

Practical Implementation

Dosing Strategy

• Start at the lowest dose and titrate slowly to minimize gastrointestinal side effects 5
  • Semaglutide: Start 0.25 mg weekly, increase to 0.5 mg at week 4, then 1 mg at week 8, target 2.4 mg 5
  • Tirzepatide: Start 2.5 mg weekly, increase by 2.5 mg increments every 4 weeks to target dose 6

Monitoring

• Monitor for symptomatic arrhythmias, though the evidence suggests reduced rather than increased risk 5, 1, 2
• Given the pacemaker, rhythm monitoring is already in place
• Weight and metabolic parameters every 4-12 weeks
• These medications require long-term use—weight regain occurs with discontinuation (11.6% regain at 52 weeks post-cessation in STEP-4) 5

Contraindications to Consider

• Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (contraindication for both agents) 5, 6
• History of pancreatitis (use with caution) 5
• Severe gastroparesis (avoid) 5

Common Pitfalls

• Gastrointestinal adverse events (nausea, vomiting, diarrhea) are dose-dependent and more frequent with rapid titration—slow escalation is critical 5
• Do not discontinue prematurely if the patient experiences transient GI symptoms—these typically improve with continued use 5
• Ensure adequate hydration, especially given COPD and potential for dehydration-related kidney injury 6

Safety in Heart Failure and COPD

The 2026 tirzepatide study specifically in patients with AF and COPD showed lower odds of COPD exacerbation (OR 0.586) and heart failure exacerbation (OR 0.270), along with reduced all-cause mortality (OR 0.145). 4 This addresses concerns about safety in your patient's specific comorbidity profile.

The STEP-HFpEF trials demonstrated that semaglutide is safe and effective in patients with heart failure and preserved ejection fraction, with fewer serious adverse events compared to placebo. 3, 7